Processa Pharmaceuticals Files Current Report
Ticker: PCSA · Form: 8-K · Filed: Feb 11, 2025 · CIK: 1533743
| Field | Detail |
|---|---|
| Company | Processa Pharmaceuticals, Inc. (PCSA) |
| Form Type | 8-K |
| Filed Date | Feb 11, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: current-report, sec-filing, listing
Related Tickers: PCSA
TL;DR
PCSA 8-K filed Feb 11, 2025. Nasdaq listing confirmed.
AI Summary
Processa Pharmaceuticals, Inc. reported on February 11, 2025, that its common stock trades under the ticker PCSA on the Nasdaq Capital Market. The company is incorporated in Delaware and its principal executive offices are located in Hanover, Maryland. This filing is a routine current report, indicating no specific material events are being disclosed at this time.
Why It Matters
This 8-K filing serves as a notification to the SEC and investors about the company's status and registered securities. It confirms the company's trading information on the Nasdaq.
Risk Assessment
Risk Level: low — This filing is a standard current report (8-K) and does not disclose any new material events, financial changes, or significant business developments.
Key Players & Entities
- Processa Pharmaceuticals, Inc. (company) — Registrant
- February 11, 2025 (date) — Date of earliest event reported
- 001-39531 (other) — Commission file number
- Delaware (jurisdiction) — State of Incorporation
- 45-1539785 (other) — I.R.S. Employer Identification Number
- 7380 Coca Cola Drive , Suite 106 , Hanover , Maryland 21076 (address) — Address of Principal Executive Offices
- (443) 776-3133 (phone_number) — Registrant's Telephone Number
- PCSA (ticker) — Trading symbol for common stock
- Nasdaq Capital Market (exchange) — Name of exchange where common stock is registered
FAQ
What is the primary purpose of this Form 8-K filing?
This Form 8-K is a Current Report filed by Processa Pharmaceuticals, Inc. to report information deemed material to investors, though this specific filing appears to be a routine update confirming basic company information and its Nasdaq listing.
What is the ticker symbol for Processa Pharmaceuticals, Inc. common stock?
The ticker symbol for Processa Pharmaceuticals, Inc. common stock is PCSA.
On which exchange is Processa Pharmaceuticals, Inc. common stock traded?
Processa Pharmaceuticals, Inc. common stock is traded on the Nasdaq Capital Market.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is February 11, 2025.
Where are Processa Pharmaceuticals, Inc.'s principal executive offices located?
Processa Pharmaceuticals, Inc.'s principal executive offices are located at 7380 Coca Cola Drive, Suite 106, Hanover, Maryland 21076.
Filing Stats: 531 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2025-02-11 10:32:39
Filing Documents
- form8-k.htm (8-K) — 38KB
- ex99-1.htm (EX-99.1) — 20KB
- ex99-1_001.jpg (GRAPHIC) — 368KB
- ex99-1_002.jpg (GRAPHIC) — 673KB
- ex99-1_003.jpg (GRAPHIC) — 358KB
- ex99-1_004.jpg (GRAPHIC) — 216KB
- ex99-1_005.jpg (GRAPHIC) — 382KB
- ex99-1_006.jpg (GRAPHIC) — 296KB
- ex99-1_007.jpg (GRAPHIC) — 391KB
- ex99-1_008.jpg (GRAPHIC) — 424KB
- ex99-1_009.jpg (GRAPHIC) — 448KB
- ex99-1_010.jpg (GRAPHIC) — 231KB
- ex99-1_011.jpg (GRAPHIC) — 309KB
- ex99-1_012.jpg (GRAPHIC) — 333KB
- ex99-1_013.jpg (GRAPHIC) — 331KB
- ex99-1_014.jpg (GRAPHIC) — 312KB
- ex99-1_015.jpg (GRAPHIC) — 270KB
- ex99-1_018.jpg (GRAPHIC) — 346KB
- ex99-1_019.jpg (GRAPHIC) — 263KB
- ex99-1_020.jpg (GRAPHIC) — 278KB
- ex99-1_021.jpg (GRAPHIC) — 271KB
- ex99-1_022.jpg (GRAPHIC) — 353KB
- ex99-1_023.jpg (GRAPHIC) — 328KB
- ex99-1_024.jpg (GRAPHIC) — 362KB
- ex99-1_025.jpg (GRAPHIC) — 359KB
- ex99-1_026.jpg (GRAPHIC) — 279KB
- ex99-1_027.jpg (GRAPHIC) — 386KB
- 0001493152-25-005830.txt ( ) — 12029KB
- pcsa-20250211.xsd (EX-101.SCH) — 3KB
- pcsa-20250211_lab.xml (EX-101.LAB) — 33KB
- pcsa-20250211_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
01. Regulation Disclosure
Item 7.01. Regulation Disclosure. A copy of a slide presentation (Presentation Materials") that Processa Pharmaceuticals, Inc. ("Processa Pharmaceuticals") intends to publish to its website, is attached to this Current Report on Form 8-K and Exhibit 99.1. The Presentation Materials speak as of the date of this Current Report on Form 8-K. While Processa Pharmaceuticals may elect to update the Presentation Materials in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, Processa Pharmaceuticals specifically disclaims any obligation to do so. The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by reference in such a filing. Item 9.01. Financial Statements and Exhibits. Exhibit No. Exhibit Description 99.1 Processa Pharmaceuticals Investor Presentation dated February 2025. 104 Cover Page Interactive Data File (formatted as Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized, on February 11, 2025. PROCESSA PHARMACEUTICALS, INC. Registrant By: /s/ George Ng George Ng Chief Executive Officer